NOVARTIS

Cosentyx Rheum - Case studies - HCP

Prescribing information

Image

Image

Cosentyx® (secukinumab) case studies: a decade of real-world clinical experience[1,2]

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adults (alone or in combination with methotrexate [MTX]) who have responded inadequately to disease-modifying anti-rheumatic drug therapy.[3]

Full indications for Cosentyx can be found here

Cosentyx Summary of Product Characteristics (SmPC) can be found here

Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.

Case study videos on demand

A decade of ... Looking to the future

Image

'I am an academic rheumatologist for Leeds in the UK, here to discuss long-term use of Cosentyx in people with PsA. Let's start with Lisa, a 45-year-old female who was diagnosed with PsA in 2006. She presented with joint symptoms affecting multiple joints, inflammation at entheseal sites and moderate skin disease...'

Prof. Philip Conaghan
Consultant Rheumatologist and Director of the NIHR Leeds Biomedical Research Centre

Watch our latest recording featuring **Professor Philip Conaghan** as he takes us through one of his long-term patients with PsA, exploring key data and treatment decisions over the years.



VIDEO

Choose Cosentyx for your eligible patients, an IL-17A inhibitor with

over a decade of experience and a consistent safety profile across indications[1-3]

Image

- **150+** clinical trials across indications[4]
- **10+** years of real-world clinical experience by healthcare professionals*[1,2]
- **8** indications[3]

The most frequently reported adverse reactions are upper respiratory tract infections (17.1%) (most frequently nasopharyngitis, rhinitis).[3]

Image

*Since first indication in 2015 for eligible adults with moderate to severe PsO.[1]

Explore efficacy outcomes in PsA

Learn more

Find out more about Cosentyx’s safety profile

Learn more

Image

Efficacy in axSpA

Image

Efficacy in JIA

Image

Safety profile

Image

Dosing

Image

Mechanism of action

Image

Contact us

Image

HCP resources

Therapeutic Indications[3]

Cosentyx is indicated for the treatment of moderate to severe PsO in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active PsA in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe HS (acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX)

whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.[3]

AS, ankylosing spondylitis; ERA, enthesitis-related arthritis; HS, hidradenitis suppurativa; IL-17, interleukin 17A; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, psoriasis; SmPC, summary of product characteristics.

References

1. European Medicines Agency. Summary of positive opinion. EMA/CHMP/670627/2015. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx_en.pdf [Accessed July 2025].

2. European Medicines Agency. Assessment report: Cosentyx. EMA/CHMP/389874/2014. Available at: https://www.ema.europa.eu/en/documents/assessment-report/cosentyx-epar-public-assessment-report_en.pdf [Accessed July 2025].

3. Cosentyx® (secukinumab) Summary of Product Characteristics.

4. ClinicalTrials.gov. Secukinumab search results. Available at: https://www.clinicaltrials.gov/search?term=Secukinumab&aggFilters=status:com%20rec%20act [Accessed July 2025].

5. Novartis Data on File. Secukinumab (SEC018). February 2025.

UK | July 2025 | FA-11463462

Source URL:
https://www.pro.novartis.com/uk-en/medicines/rheumatology/cosentyx/case-studies